News brief
On 2026-06-18, according to Xiniu Data, Lingchuangyigu completed Series B+ financing, raising RMB 200 million. Investors were Suzhou Chuangjinglinghang Venture Capital Partnership (Limited Partnership), Zhongjin Capital. The company is a developer of neuromodulation and brain-computer interface medical devices.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年6月18日，据烯牛数据报道，领创医谷完成B+融资，金额2亿人民币。投资方为苏州创景领航创业投资合伙企业（有限合伙），中金资本。该公司为神经调控及脑机接口医疗器械研发商。